Insurance Companies' Poor Adherence to Guidelines for Moderate-to-Severe Ulcerative Colitis/Crohn's Disease Management.
Am J Gastroenterol
; 2024 Mar 15.
Article
en En
| MEDLINE
| ID: mdl-38417043
ABSTRACT
INTRODUCTION:
Moderate-to-severe inflammatory bowel disease treatment transitioned from step-up therapy to induction of remission with a biologic agent, but insurance coverage varies.METHODS:
Top 50 insurance companies were searched for publicly available policies for 5 biologic/small molecule agents. Data regarding coverage requirements were compared with American College of Gastroenterology/American Gastroenterological Association guidelines.RESULTS:
Thirty-four insurers had public policies. Adherence to American College of Gastroenterology/American Gastroenterological Association guidelines ranged from 5.8% to 58.8%. Only 14.71% and 17.65% of policies permitted any first-line biologic therapy in Crohn's disease and in ulcerative colitis.DISCUSSION:
Nearly every insurance company required failure of steroids and immunomodulators before biologic therapy. Further work is required to improve patient access to standard-of-care treatment.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
Am J Gastroenterol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos